Efficacy and tolerability of liraglutide in combination with other antidiabetic drugs in type 2 diabetes

Acta Biomedica

Volumn 82, Issue 3, 2011, Pages 251-253

  Zenari, Luciano ^a  

^a Direttore UO Diabetologia Ospedale Sacro Cuore Negrar   (Italy)

Author keywords

GLP 1 receptor agonists; Liraglutide; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; MIDDLE AGED;

EID: 84860790016     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Garber AJ. Long-acting GLP-1 receptor agonists. Diabetes Care 2011; 34 (2): S279-82.
2. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm forthe initiation and adjustment of therapy: a consensus state-ment from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29 (8): 1963-72.
3. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-81.
4. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608-10.
5. Astrup A, Rössner S, Van Gaal L, et al. NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009; 374 (9701): 1606-16.
6. Tahrani AA, Bailey CJ, Barnett AH. Management of type 2 diabetes: new and future developments in treatments. Lancet 2011; 378: 182-96.
7. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187-218.